Antiarrhythmic efficiency of Craviten and changes in the activities of serum dopamine beta-hydroxylase and erythrocyte membrane ATPases
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
3024906
Knihovny.cz E-zdroje
- MeSH
- adenosintrifosfatasy krev MeSH
- antiarytmika terapeutické užití MeSH
- Ca(2+)-Mg(2+)-ATPasa krev MeSH
- dopamin-beta-hydroxylasa krev MeSH
- erytrocytární membrána metabolismus MeSH
- ethylendiaminy terapeutické užití MeSH
- lidé MeSH
- pulz účinky léků MeSH
- sodíko-draslíková ATPasa krev MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adenosintrifosfatasy MeSH
- antiarytmika MeSH
- butobendin MeSH Prohlížeč
- Ca(2+)-Mg(2+)-ATPasa MeSH
- dopamin-beta-hydroxylasa MeSH
- ethylendiaminy MeSH
- magnesium sodium potassium ATPase MeSH Prohlížeč
- sodíko-draslíková ATPasa MeSH
Among 30 patients with ventricular arrhythmia resistant to conventional antiarrhythmic therapy, 33% showed normalization of heart rhythm after single i.v. injection of Craviten at a dose of 6 mg. In all patients, sensitive and resistant to this dose of Craviten, serum dopamine beta-hydroxylase activity was initially twice as high as that in healthy controls. After Craviten administration, enzyme activity normalized in the sensitive persons only, parallelly with rhythm normalization. In this group of patients the initially increased erythrocyte membrane ATPase activities (total and ouabain-insensitive) also normalized.